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Background and purpose: Cardiac myxoma is a rare etiology of stroke. Both cerebral
microbleeds and cardiac myxoma may increase the risk of intracerebral hemorrhage after
intravenous (IV) thrombolysis. However, data are still limited. We report a case of multiple
cerebral microbleeds treated with IV thrombolysis with later findings of cardiac myxoma.
Summary of case: A 58-year-old-man presented with right-sided hemiplegia and global
aphasia. The presumptive diagnosis of acute left middle cerebral artery (MCA) infarction
was made. Previous magnetic resonance imaging showed multiple cerebral microbleeds.
The patient received IV thrombolysis. Bilateral cerebellar hemorrhage occurred after throm-
bolysis, and a median suboccipital craniectomy and hematoma removal was performed.
Transthoracic echocardiogram found a left atrial myxoma. The tumor was then surgically
removed. Six months later, neurological deficit improved.
Conclusion: Cerebral microbleeds may be associated with atrial myxoma. IV thrombolysis
could benefit acute ischemic stroke patients with both baseline cerebral microbleeds and
atrial myxoma.
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INTRODUCTION
Cardiac myxoma is a rare etiology of stroke . Both cerebral microb-
leeds and cardiac myxoma may increase the risk of intracerebral
hemorrhage (ICH) after IV thrombolysis (1–4). However, data are
still limited. We report a patient with multiple cerebral microb-
leeds who was treated with thrombolysis and was later found to
have cardiac myxoma.
CASE REVIEW
A 58-year-old Thai male with hypertension and previous ischemic
stroke 4 months earlier, developed a sudden onset of right-sided
weakness and was unable to speak 2 h prior to hospital arrival.
His blood pressure was well controlled (<140/90 mmHg) with
amlodipine 5 mg/day before and after his previous ischemic stroke.
Aspirin 81 mg and simvastatin 20 mg/day were given after pre-
vious stroke. At the emergency room, his blood pressure was
158/89 mmHg and pulse was 82 beats per minute (regular) with
regular heart rate and rhythm. There were no cardiac murmurs
on auscultation. The patient was alert but had global aphasia
with forced eye deviation to the left. Right facial weakness (upper
motor neurons), right hemiplegia, right hypoanesthesia, and right
homonymous hemianopia were found. The NIH Stroke Scale
(NIHSS) was 20. Complete blood cell count, coagulation profile,
plasma level of glucose, electrolytes, renal and liver function tests
were normal. An electrocardiogram demonstrated normal sinus
rhythm with a rate of 80 beats per minute. Non-contrast computed
tomography (CT) scan of the head demonstrated no evidence of
acute ischemic or hemorrhagic stroke (Figure 1). The diagnosis
of acute left MCA infarction was made and cardiogenic embolism
was highly suspected. Patient’s magnetic resonance imaging (MRI)
and magnetic resonance angiography (MRA) performed after the
previous stoke 4 months earlier were reviewed and demonstrated
infarction in both cerebellar hemispheres and right parietal deep
white matter area. Multiple microbleeds were also noted pre-
dominantly at basal ganglia, thalamus, and cerebellum, bilaterally
(Figure 2). Despite the microbleeds on the previous MRI, the
stroke neurologist felt that there was no absolute contraindication
for intravenous (IV) thrombolysis. Therefore, IV tissue plasmino-
gen activator was given 140 min after stroke onset. Computed
tomography angiography (CTA) and perfusion study (CTP) were
subsequently performed 1 h after thrombolysis treatment initia-
tion. CTP showed a delayed time to peak (TTP) and mean transit
time (MTT) with preservation of cerebral blood volume (CBV) at
the left parieto-occipital region, which is likely to indicate the pres-
ence of ischemic penumbra. However, no significant stenosis of
MCA was found on CTA thus mechanical thrombectomy was not
performed. Standard post-IV thrombolysis care protocol, includ-
ing close blood pressure monitoring, was carried out. Patient con-
tinued to have right hemiplegia and global aphasia with a NIHSS
of 20. A non-contrast CT scan of the brain 24 h after thrombol-
ysis revealed a hematoma at the left cerebellum with perilesional
edema and multiple foci of hyperdense lesion at right cerebel-
lum, superior frontal gyrus, and left temporal lobe consistent with
hemorrhagic transformation (parenchymal hematoma type 2) (5)
(Figure 3). Patient symptoms worsened between 24 and 48 h post-
IV thrombolysis, he was stuporous and NIHSS progressed from
20 to 22. Repeated CT brain 3 days after thrombolytic treatment
showed worsening of the left cerebellar edema. Patient underwent
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FIGURE 1 | Pre-treatment non-contrast brain CT scan. (A,B) There was no evidence of acute ischemic or hemorrhagic stroke.
FIGURE 2 | Brain MRI performed during the previous ischemic stroke
4 months earlier. (A–D) DWI showed restricted fluid diffusion in cerebellar
hemispheres, left temporal cortex, right parietal deep white matter consistent
with acute infarctions. (E–H) SWI-MRI (susceptibility weighted imaging MRI)
showed multiple cerebral microbleeds, particularly in the deep gray matter
and posterior fossa, possibly due to hypertensive vasculopathy.
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FIGURE 3 | Non-contrast brain CT scan 1 day after thrombolysis.
(A) Round shaped (3.1 cm×3.2 cm×2.3 cm) hyperdense lesion occupying
the left cerebellum and foci of hyperdense lesion in right cerebellum.
(B) Foci of hyperdense lesion in left temporal lobe.
a median suboccipital craniectomy and hematoma evacuation
and thereafter his condition resulted as clinically stable without
evidence of brainstem compression. As part of the protocol for
the etiologic diagnosis of stroke, a transthoracic echocardiogram
(TTE) was performed revealing a large (55 mm× 25 mm) mobile,
lobulated, heterogeneous echoic mass with scattered calcification
attached to interatrial septum with in and out protrusion of the
mitral annular plane. A highly mobile component at the surface of
left atrial mass was also present. Findings were consistent with both
left atrial myxoma and superimposed thrombus (Figure 4). After
discussion of the clinical case, informed consent was given by the
patient’s family to surgically remove the atrial myxoma. Patho-
logical examination confirmed the diagnosis of myxoma. There
was a piece of gelatinous tissue (4 cm× 2.5 cm× 0.8 cm) attached
to a part of tumor stalk. Histopathological examination revealed
that the tumor extended into the venous channel on underlying
myocardium. The resection margin was free of tumor (Figure 5)
and after 31 days of admission, the patient was discharged to return
home. At time of discharge, he still had right hemiplegia and global
aphasia, NIHSS was 16, Barthel index 0, and the modified Rankin
Scale (mRS) 5. After 6 months, his clinical condition was signifi-
cantly improved, including gait and speech. NIHSS was 7, Barthel
index 25, and mRS 4. At 9 months, the patient was able to engage
in walking without assistance, the NIHSS was 5, Barthel index 65,
and mRS 3.
DISCUSSION
We report a case of IV thrombolysis treatment in patient with atrial
myxoma and cerebral microbleeds. The patient had a previous
ischemic stroke 4 months earlier and was known to have multiple
cerebral microbleeds in bilateral deep gray matter and posterior
fossa on MRI. He developed acute ischemic stroke in the MCA
territory and received IV thrombolysis despite the presence of mul-
tiple cerebral microbleeds. Investigations later found that he had
atrial myxoma, which may have been the cause of the microbleeds.
Another possible cause of cerebral microbleeds is his history of
hypertension. However, the patient had good control of his blood
FIGURE 4 |Transthoracic echocardiogram findings. A large
(55 mm×25 mm) mobile and lobulated heterogeneous echogenic mass
with scatter calcification attached to interatrial septum and in and out
protrusion of mitral annular plane, highly mobile with thrombus on top.
Findings were consistent with left atrial myxoma with superimposed
thrombus.
pressure. He developed symptomatic intracerebral hemorrhage
(sICH) after thrombolytic treatment (6), which required surgical
decompression.
This case has three major points of interest. Firstly, it sup-
ports the previous finding that cerebral microbleeds and previous
stroke increase the risk of ICH after thrombolysis. Our patient
developed sICH 1 day after receiving IV thrombolysis, which is
consistent with results from two meta-analyses showing trends of
increased risk of sICH after thrombolysis in patients with microb-
leeds (3, 4). Moreover, there was a significant association between
increased cerebral microbleeds burden and the risk of any ICH and
sICH after thrombolysis (1). Our patient also had high burden of
cerebral microbleeds (>10 microbleeds).
For bleeding location after thrombolysis, a small study of eight
acute ischemic stroke patients with cerebral microbleeds receiving
thrombolysis found that the hemorrhage always occurs at the area
of the ischemic stroke, whereas none of the ICH occurred at the
site of cerebral microbleeds (7). In our patient, ICH was found
in the cerebellum at the site of cerebral microbleeds and at the
site of previous ischemic area. Although the cerebral microbleeds
in this patient may be attributable to hypertension, the site of
microbleeds is unusual. Microbleeds in the cerebellum are found
in 17% of cases; moreover, microbleeds in the cerebellum are likely
to be located medially near dentate nuclei (8). In our patient,
microbleeds were found to be located peripherally in the cerebellar
hemisphere.
To date, the risk of ICH after thrombolysis in patients with
cerebral microbleeds is still uncertain and there are no recom-
mendations to prevent patients from receiving IV thrombolysis
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FIGURE 5 | Pathology findings. (A,B) Gelatinous tissue
(4 cm×2.5 cm×0.8 cm) attached to part of tumor stalk
(1.5 cm×1 cm×0.5 cm). (C) Extension of tumor tissue into trabecule and
venous channel. (D) Tumor cells: spindle or stellate shape, eosinophilic
cytoplasm, and bland-looking nuclei. Tumor cells were located in myxoid
stroma and surrounded by numerous red blood cells.
in the presence of cerebral microbleeds on MRI (9). Although
there is no definite contraindication for thrombolysis in our
patient according to the current guidelines, special precaution is
needed in patients with history of previous stroke and microb-
leeds especially if the cause of microbleeds is related to atrial
myxoma.
The second and probably more important aspect of this clinical
case is the cause of stroke and microbleeds. Cerebral microbleeds
has been detected in several medical conditions such as hyper-
tensive vasculopathy, cerebral amyloid angiopathy (CAA), diffuse
axonal injury after head trauma, or cardiac myxoma (10, 11). Clin-
ical course of patients and distribution of cerebral microbleeds can
be helpful for differentiating the etiology of cerebral microbleeds.
Cerebral microbleeds in the basal ganglia, thalamus, brainstem,
and cerebellum typically result from hypertensive vasculopathy.
However, our patient had his hypertension well under control and
also had cerebral microbleeds located in the peripheral areas of the
brain. CAA, which mostly occurs in the elderly and where mul-
tiple cerebral microbleeds are usually restricted to lobar, cortical,
or cortico-subcortical areas, especially posterior cortical regions,
is unlikely in our patient. This patient did not have previous head
injury, and microbleeds were not located in the frontal and tem-
poral regions, hence we can rule out head trauma-related diffuse
axonal injury.
Atrial myxoma is a rare cause of stroke. Cerebral
embolism leading to ischemic stroke, aneurysmal formation, and
myxomatous metastasis are common neurological complications.
In this case report, we found that multiple microbleeds and recur-
rent territorial infarction can be associated with the presence of
as atrial myxoma. To our knowledge, there is only one report
of microbleeds as a complication of atrial myxoma (12). Patho-
logical findings of the brain in patients with atrial myxoma are
generally consistent with multiple infarctions. Aneurysmal for-
mation and pseudoaneurysms can be found at the site of vascular
occlusion. It has been proposed that tumor cells may infiltrate
cerebral vessels via vasa vasorum and subsequently proliferate
in the vessel wall, leading to a weakening of the internal elas-
tic lamina and aneurysmal formation. This process is similar to
the mechanism underlying the formation of mycotic aneurysms.
Sometimes, rupturing of the three layers of the arterial wall occurs
and pseudoanerysms are formed. These pseudoaneurysms gener-
ally grow faster than the true aneurysm itself and can result in
hemorrhage. Microembolism has also been demonstrated in the
retina of patients with atrial myxoma (13). We proposed that small
myxoma particles, which embolize and lodge in the small vessels
in the brain may lead to formation of microbleeds.
The third and possibly the most important point in this
patient is the risk of bleeding after thrombolysis in patients with
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Table 1 | Characteristics of patients with acute ischemic stroke due to cardiac myxoma receiving intravenous thrombolysis.
Reference Year Age/sex OTT min NIHSS Location ICH within 7 days
of stroke onset
Outcome
Chong (3) 2005 74/F 180 6 Left MCA Yes Aphasia
Cerebellum
Left parietal SAH
Ibrahim (14) 2008 51/M 84 22 Left MCA No Complete recovery
Nagy (15) 2009 26/M 105 10 Right MCA No Minimal hand weakness at 2 years
Ong (16) 2011 22/F 125 12 Right MCA No NIHSS 5 at 10 months
Sun (17) 2011 45/M 172 16 Left MCA No Motor aphasia
Acampa (4) 2011 63/F 160 19 Right MCA Yes Slight improved NIHSS 15 at day 25
Right parietal
Ruzicka – Kaloci (18) 2012 42/F − 17 Left MCA No NIHSS 8
Hatayama (19) 2012 76/M 155 − Left MCA No Improved
Our case report 2014 58/M 140 20 Left MCA Yes Improved at 6 months
Cerebellum Able to walk with assistance
Some aphasia
ICH, intracerebral hemorrhage; MCA, middle cerebral artery; NIHSS, National Institute of Health Stroke Scale; OTT, onset to treatment time; SAH, subarachnoid
hemorrhage.
myxoma and cerebral microbleeds. Embolized myxoma parti-
cles generally lodge in brain arteries and proliferate in the ves-
sel wall. Pseudoaneurysm and aneurysm formation in the small
arteries may be more vulnerable to thrombolysis induced ICH.
There were nine reports of patients, including ours, with acute
ischemic stroke due to cardiac myxoma who received IV throm-
bolysis (3, 4, 14–19) (Table 1). All patients developed ischemic
stroke in the MCA territory and received IV thrombolysis within
3 h after stroke onset. Three out of nine patients, including
our patient, developed ICH after IV thrombolysis. Bleeding was
found located in the cerebellum and parietal lobe. Our patient
was the only case with reported evidence of multiple cerebral
microbleeds on MRI. Other authors did not report any data on
microbleeds. Among these case reports, most patients, includ-
ing ours, improved after thrombolysis and had a good clinical
outcome. Due to the invasive nature of embolized myxoma-
tous material in the cerebral vessel, special precaution should
be taken with IV thrombolysis in patients with a diagnosis of
atrial myxoma, especially in those with evidence of cerebral
microbleeds.
We propose that in case of involvement of several arterial ter-
ritories, physicians should consider cardioembolic stroke in the
differential diagnosis and continue aggressive work up, to adopt
the most appropriate therapeutic strategies and prevent recur-
rent stroke. Ischemic stroke patients with cerebral microbleeds
and atrial myxoma may have an increased risk of bleeding from
IV thrombolysis.
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